Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAIX-targeted CAR-T Cells in Advanced Renal Cell Carcinoma
NCT04969354Phase 1Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Oct 2021
- Primary completion
- Sep 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CAIX-targeted CAR-T cells in renal cell carcinoma (RCC), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Adverse Events at 1 month and Effectiveness evaluation at 3 months. Started Oct 2021; status: recruiting.
02
Drugs
CAIX-targeted CAR-T cells
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04969354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969354.